GSK Business Summary

GSK plc (GSK) operates as a research-based global biopharmaceutical leader, generating revenue primarily through the high-margin sale and licensing of innovative specialty medicines and vaccines. Following the 2022 demerger of its consumer healthcare business (Haleon), the company has pivoted toward a product-led model concentrated in three core segments: Specialty Medicines, Vaccines, and General Medicines. Specialty Medicines, particularly in HIV, Oncology, and Respiratory, Immunology & Inflammation (RI&I), serves as the primary growth engine, while the Vaccines division maintains a market-leading position with flagship products like Shingrix and Arexvy. GSK competes directly with global pharmaceutical giants such as AstraZeneca, Novartis, Sanofi, and Pfizer; it currently maintains a top-tier market position as one of the world's ten largest pharmaceutical entities by revenue, distinguished by its dominant share in the global vaccine market and a robust pipeline of over 60 assets in clinical development. While GSK traces its origins to a 1715 pharmacy, the modern plc entity was established through the landmark 2000 merger of Glaxo Wellcome and SmithKline Beecham. The leadership team is currently led by Chief Executive Officer Luke Miels, who assumed the role on January 1, 2026, after serving as Chief Commercial Officer and holding senior executive positions at AstraZeneca and Roche. He is supported by Chief Financial Officer Julie Brown, formerly of Smith & Nephew, and Chief Scientific Officer Tony Wood, who oversees the company’s R&D reinvigoration. Shobie Ramakrishnan serves as the Chief Digital and Technology Officer, spearheading the integration of AI and data science into drug discovery. The company is overseen by Chair Sir Jonathan Symonds and is backed by major institutional investors, including Dodge & Cox, BlackRock, and Vanguard, reflecting its status as a cornerstone of the FTSE 100.